
Exin Therapeutics helps product companies improve product performance and manufacturability using advanced manufacturing technology and engineering services. The company applies manufacturing process development, automation, and materials engineering to optimize design, production, and scale-up. It operates as a B2B manufacturing technology and engineering provider serving product companies across industries. Exin's work focuses on reducing cost, improving quality, and accelerating time-to-market through technical integration of production systems and process controls. The company targets manufacturers and product developers seeking to industrialize and scale new products.

Exin Therapeutics helps product companies improve product performance and manufacturability using advanced manufacturing technology and engineering services. The company applies manufacturing process development, automation, and materials engineering to optimize design, production, and scale-up. It operates as a B2B manufacturing technology and engineering provider serving product companies across industries. Exin's work focuses on reducing cost, improving quality, and accelerating time-to-market through technical integration of production systems and process controls. The company targets manufacturers and product developers seeking to industrialize and scale new products.
Stage: Pre-Seed (YC W2025)
Headquarters: South San Francisco, CA
Product: Multimodal AI discovery platform for neurotherapeutics
Founders: Gabriel Ocana Santero; Ivan Lazarte; Marko Tvrdic
Wet lab strategy: Relocating wet lab to Manila for high-throughput in vivo datasets
Neurotherapeutics target discovery for disorders involving neural circuits.
2024
Biotechnology
Reported Pre-Seed round with Y Combinator and investor Ryan Merket; amount obfuscated in some sources.
“Y Combinator participation and investment”